Cargando…
A Case of Graves’ Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature
A 57-year-old man presented to the outpatient clinic with tremor, palpitations, weight loss and fatigue 1 week after receiving the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine (ChAdOx1 nCoV-19). Laboratory studies showed a suppressed TSH with elevated total and free T4. Thyroid peroxidase...
Autores principales: | Cuenca, Dalia, Aguilar-Soto, Mercedes, Mercado, Moisés |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SMC Media Srl
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067422/ https://www.ncbi.nlm.nih.gov/pubmed/35520363 http://dx.doi.org/10.12890/2022_003275 |
Ejemplares similares
-
Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021) -
Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021) -
Monoarthritis induced by the Oxford-AstraZeneca(R) SARS-CoV-2 vaccine
por: Schoenardie, Bruna Ossanai, et al.
Publicado: (2022) -
Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?
por: Østergaard, Søren Dinesen, et al.
Publicado: (2021) -
Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?
por: Cross, Samuel, et al.
Publicado: (2021)